Loading
A phase 3 trial of Cemiplimab, Docetaxel, Vinorelbine and Gemcitabine in non-small-cell lung cancer, run by Maia Biotechnology, now recruiting.
A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC is a phase 3 interventional study registered as NCT06908304 by Maia Biotechnology, with 300 participants planned, started 2025-12-08 and due to reach its primary completion in 2027-07-31. Interventions recorded: 6-Thio-2'-Deoxyguanosine, Cemiplimab, Docetaxel, Vinorelbine and Gemcitabine alone.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Maia Biotechnology, Cemiplimab, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Shares Vinorelbine, Docetaxel, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Gemcitabine, Non-small-cell lung cancer and the tag pipeline.
Shares Vinorelbine, Gemcitabine and the tag pipeline.
Shares Vinorelbine, Gemcitabine and the tag pipeline.
Shares Docetaxel, Gemcitabine and the tag pipeline.
Shares Docetaxel, Non-small-cell lung cancer and the tag pipeline.
Shares Docetaxel, Immune checkpoint inhibitors, Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/